Search

Recursion Pharmaceuticals Inc

Fechado

SetorSaúde

3.24 -7.16

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.22

Máximo

3.49

Indicadores-chave

By Trading Economics

Rendimento

-14M

-131M

Vendas

1.2M

7.7M

EPS

-0.25

Margem de lucro

-1,708.018

Funcionários

600

EBITDA

-10M

-113M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+83.71% upside

Dividendos

By Acuity

Próximos Ganhos

4 de nov. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-20M

1.7B

Abertura anterior

10.4

Fecho anterior

3.24

Recursion Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de ago. de 2026, 20:02 UTC

News
Correlated Moves

Recursion Pharmaceuticals Inc shares are lower amid broader market declines, with analysts rating the stock as a "Hold" and price targets between $5.30 and $10.00.

21 de ago. de 2026, 20:06 UTC

Recursion Pharmaceuticals Inc shares are higher during Friday's session, reflecting strong momentum since Thursday's close amid favorable conditions in the biotechnology sector.

20 de ago. de 2026, 20:06 UTC

Social Media
Correlated Moves

Recursion Pharmaceuticals Inc shares are lower today, reflecting broader market trends. The stock's decline aligns with weakness in correlated assets.

19 de ago. de 2026, 23:01 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours after a volatile session, declining from the upper end of its one-month range.

18 de ago. de 2026, 20:04 UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares are lower today amid broader market pressures on small-cap stocks and rising U.S. Treasury yields affecting sentiment.

17 de ago. de 2026, 19:36 UTC

Correlated Moves
News

Recursion Pharmaceuticals shares decline as Morgan Stanley cuts the price target to $5.30 from $5.50, reflecting ongoing valuation concerns.

12 de ago. de 2026, 19:56 UTC

Recursion Pharmaceuticals Inc is trading lower, reflecting a decline from Tuesday's close. The stock remains above its 20-day moving average despite today's pullback.

11 de ago. de 2026, 19:36 UTC

News

Recursion Pharmaceuticals Inc. is higher today amid positive market sentiment and over $500 million in milestone payments from partnerships with Genentech/Roche and Sanofi.

10 de ago. de 2026, 20:06 UTC

Social Media

Recursion Pharmaceuticals Inc is higher Monday amid ongoing interest, despite social media concerns about its clinical pipeline and integration challenges with Exscientia.

7 de ago. de 2026, 23:26 UTC

Recursion Pharmaceuticals Inc. shares have been roughly flat in after-market trading, with minimal fluctuations since Friday's close. The stock remains above its 20-day moving average.

6 de ago. de 2026, 23:26 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting a slight decline since Thursday's close amid a strengthening U.S. Dollar.

5 de ago. de 2026, 23:41 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours, amid declining sentiment in US markets despite positive momentum in Asian indices.

4 de ago. de 2026, 23:31 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours following a volatile session with no specific news to explain the movement.

3 de ago. de 2026, 20:03 UTC

Correlated Moves
News

Recursion Pharmaceuticals Inc shares are higher amid strong market sentiment, supported by a rise in the Russell 2000 Index and notable intraday volatility.

31 de jul. de 2026, 23:32 UTC

News

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting broader market trends amid mixed performance among major tech stocks and upcoming economic data.

30 de jul. de 2026, 23:26 UTC

Recursion Pharmaceuticals Inc. shares were roughly flat in after-market hours, trading within a narrow range since Thursday's close, significantly below its 20-day moving average.

29 de jul. de 2026, 22:51 UTC

Recursion Pharmaceuticals Inc is higher in after-market trading, reflecting broader market gains amid the Federal Reserve's decision to maintain interest rates.

28 de jul. de 2026, 23:11 UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares declined in after-market hours, influenced by a broader market downturn and declines in tech stocks amid AI investment concerns.

27 de jul. de 2026, 23:46 UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares are lower in after-market trading, reflecting broader market trends despite gains in the DAX 30 Index amid mixed results across indices.

24 de jul. de 2026, 23:11 UTC

Recursion Pharmaceuticals Inc shares rose during after-market hours, gaining momentum despite being near the lower end of their one-month trading range.

23 de jul. de 2026, 19:16 UTC

Recursion Pharmaceuticals Inc. shares are trading roughly flat, remaining below their 20-day moving average amid limited upward momentum in broader market dynamics.

22 de jul. de 2026, 23:36 UTC

Recursion Pharmaceuticals Inc. shares are near unchanged in after-market hours. The stock remains below its 20-day moving average amid rising crude oil prices.

21 de jul. de 2026, 23:51 UTC

Recursion Pharmaceuticals Inc's shares are lower in after-market hours, settling down from Tuesday's close without any specific news to explain the movement.

20 de jul. de 2026, 19:46 UTC

Correlated Moves

Recursion Pharmaceuticals is declining, continuing a trend from previous sessions, amid broader declines in the ARK Genomic Revolution ETF and Russell 2000 Index.

Comparação entre Pares

Variação de preço

Recursion Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

83.71% parte superior

Previsão para 12 meses

Média 6.43 USD  83.71%

Máximo 8 USD

Mínimo 5.3 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Recursion Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

4 ratings

1

Comprar

3

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat